PAXLOVID cpr pell 4x150mg/2x100mg 5 x 6 pce
7680687930017
CH-68793
J05AE30
08.03.0.
Reimbursement limitations:
PAXLOVID.01
PAXLOVID est remboursé en tant que monothérapie antivirale pour le traitement d’une infection COVID-19 confirmée …
1 / 3
google
Details
- Product number
- 6879301
- CPT
- -
- Packaging group
- 30
- Unit
- Tablette(n)
- Composition
- A): nirmatrelvirum 150 mg, cellulosum microcristallinum, lactosum monohydricum 185 mg, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, Überzug: hypromellosum, E 171, macrogolum 400, E 172 (rubrum), pro compresso obducto corresp. natrium 0.99 mg. B): ritonavirum 100 mg, copovidonum, silica colloidalis anhydrica, sorbitani lauras, calcii hydrogenophosphas, natrii stearylis fumaras, Überzug: hypromellosum, E 171, macrogolum 400, macrogolum 3350, hydroxypropylcellulosum, talcum, silica colloidalis anhydrica, polysorbatum 80, pro compresso obducto, natrium 0.388 mg.
Articles (1)
Paxlovid, Filmtabletten
Filmtabletten
30
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
B
|
100.0 MG | Substance | Wirkstoff (Principe actif) |
|
A
|
150.0 MG | Substance | Wirkstoff (Principe actif) |
|
A
|
- | Substance | HNIDK |
|
B
|
- | Substance | HNIDK |
|
A
|
185.0 MG | Substance | HBESI |
|
B
|
- | Substance | HNIDK |
|
A
|
- | Substance | HNIDK |
|
B
|
- | Substance | HNIDK |
|
A
|
- | Substance | HNIDK |
|
B
|
- | Substance | HNIDK |
|
B
|
- | Substance | HNIDK |
|
A
|
- | Substance | HNIDK |
|
B
|
- | Substance | HNIDK |
|
A
|
- | Substance | HNIDK |
|
B
|
- | Substance | FNIDK |
|
A
|
- | Substance | FNIDK |
|
A
|
- | Substance | Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration) |
|
B
|
- | Substance | Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration) |
|
B
|
- | Substance | HNIDK |
|
A
|
- | Substance | FTODK |
|
B
|
- | Substance | HNIDK |
|
B
|
- | Substance | HNIDK |
|
A
|
0.99 MG | Substance | HBESI |
|
B
|
- | Substance | HNIDK |
|
B
|
- | Substance | HNIDK |
|
B
|
0.388 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 1058.95
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/12/2023
Authorization holder
Pfizer AG
8052 Zürich
Authorization information
- Swissmedic authorization number
- 68793
- Drug name
- Paxlovid, Filmtabletten
- Galenic form
- FILM
- ATC Code
- J05AE30
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 15/06/2022
- Authorization expiration date
- 04/04/2029
- IT number
- 08.03.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- PAXLOVID cpr pell 4x150mg/2x100mg 5 x 6 pce
- Description (DE)
- PAXLOVID Filmtabl 4x150mg/2x100mg 5 x 6 Stk
- Market launch
- 15/06/2022
- Narcotic (BTM)
- No